EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Electronic Patient-Reported Outcomes With Vital Sign Monitoring During Trastuzumab Deruxtecan Therapy

Yuichiro Kikawa, Yukari Uemura, Tetsuhiko Taira, Chiyoe Kitagawa, Hideki Maeda, Hiroaki Kato, Naoki Hashimoto, Mitsuchika Hosoda, Yohei Hamanaka, Yuko Tanabe, Tatsuya Yoshida, Kaori Tane und 8 weitere

JAMA Network Open · 15.08.2025 · 8 (8) · e2527403

DOI: 10.1001/jamanetworkopen.2025.27403 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 15.08.2025. Verfasst von Yuichiro Kikawa und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Kansai Medical University, Hirakata, Japan. Hauptthemen laut MEDLINE: Trastuzumab, Patient Reported Outcome Measures, Breast Neoplasms, Vital Signs. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Patients with ERBB2 (formerly HER2 or HER2/neu)-positive metastatic breast cancer (MBC) receiving trastuzumab deruxtecan (T-DXd), a new standard of care, may experience specific adverse events affecting their quality of life (QOL). Monitoring electronic patient-reported outcomes alongside vital signs may help improve their QOL through early detection and management of these symptoms.

Objective

To assess whether symptom tracking and vital sign monitoring improve QOL compared with usual care in patients receiving T-DXd. Design, Setting, and Participants This multicenter randomized clinical trial conducted at 38 Japanese hospitals from March 1, 2021, to December 31, 2024, assigned patients with ERBB2-positive MBC eligible for T-DXd to either a monitoring or usual care group.

Intervention

Randomization was 1:1 for the monitoring and usual care groups. Patients in the monitoring group recorded weekly symptom reports and daily body temperature and percutaneous oxygen saturation data using a smartphone or tablet. Alerts were sent to medical staff when symptom or vital sign thresholds were exceeded. Main Outcomes and Measures The primary outcome was the change from baseline in global health status scores at week 24, assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (scores range from 0 to 100, in which higher scores indicate a better quality of life and level of functioning). For symptom scales, however, higher scores indicate a worse symptom burden. Secondary outcomes included changes in functional and symptom scales, as well as survival outcomes.

Results

Of 111 female patients enrolled (mean [SD] age, 57.1 [11.0] years), 56 (50.5%) were randomized to the monitoring group and 55 (49.5%) to the usual care group. Baseline patient characteristics and QOL scores were comparable between the 2 groups. At week 24, the mean change in the global health status score from baseline was higher in the monitoring group compared with the usual care group (mean difference, 8.0 [90% CI, 0.2-15.8]; P = .09). Improvements in functional scales were noted in the monitoring group for role (mean difference, 10.0 [95% CI, 1.1-18.9]), cognitive (6.3 [95% CI, 1.1-11.5]), and social (10.9 [95% CI, 3.9-18.0]) functioning. Fatigue scores were lower in the monitoring group (mean difference, −8.4 [95% CI, −16.1 to −0.6]), although nausea or vomiting scores were similar between the groups (mean difference, 0.5 [95% CI, −6.2 to 7.1]). No significant differences were observed in survival outcomes. Conclusions and Relevance In this randomized clinical trial of patients with ERBB2-positive MBC receiving T-DXd, the findings suggest that electronic symptom and vital sign tracking may help maintain QOL or prevented its deterioration. While survival outcomes were unaffected, this monitoring strategy has potential to enhance patient-centered care. Trial Registration jRCT identifier: jRCTs031200387

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrastuzumabPatient Reported Outcome MeasuresBreast NeoplasmsVital SignsAntineoplastic Agents, ImmunologicalHumansFemaleMiddle AgedQuality of LifeAgedAdultJapan

Substanzen

TrastuzumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Breast Surgery, Kansai Medical University, Hirakata, Japan.
  • Center for Clinical Science, National Center for Global Health and Medicine, Tokyo, Japan.
  • Department of Medical Oncology, Sagara Hospital, Kagoshima, Japan.
  • Department of Medical Oncology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
  • Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
  • Department of Chest Surgery, Teine Keijinkai Hospital, Sapporo, Japan.

Zitieren

APA

Kikawa, Y., Uemura, Y., Taira, T., Kitagawa, C., Maeda, H., Kato, H., Hashimoto, N., Hosoda, M., Hamanaka, Y., Tanabe, Y., Yoshida, T., Tane, K., Takabatake, D., Ishikawa, T., Iwamoto, T., Yamaguchi, T., Takiguchi, D., Mukai, H., Taira, N., & Sangai, T. (2025). Electronic Patient-Reported Outcomes With Vital Sign Monitoring During Trastuzumab Deruxtecan Therapy. JAMA Network Open, 8(8), e2527403. https://doi.org/10.1001/jamanetworkopen.2025.27403

Vancouver

Kikawa Y, Uemura Y, Taira T, Kitagawa C, Maeda H, Kato H, et al. Electronic Patient-Reported Outcomes With Vital Sign Monitoring During Trastuzumab Deruxtecan Therapy. JAMA Network Open. 2025;8(8):e2527403. doi:10.1001/jamanetworkopen.2025.27403

BibTeX
@article{Kikawa2025,
  author = {Kikawa, Yuichiro and Uemura, Yukari and Taira, Tetsuhiko and Kitagawa, Chiyoe and Maeda, Hideki and Kato, Hiroaki and Hashimoto, Naoki and Hosoda, Mitsuchika and Hamanaka, Yohei and Tanabe, Yuko and Yoshida, Tatsuya and Tane, Kaori and Takabatake, Daisuke and Ishikawa, Takashi and Iwamoto, Takayuki and Yamaguchi, Takeshi and Takiguchi, Daisuke and Mukai, Hirofumi and Taira, Naruto and Sangai, Takafumi},
  title = {Electronic Patient-Reported Outcomes With Vital Sign Monitoring During Trastuzumab Deruxtecan Therapy},
  journal = {JAMA Network Open},
  year = {2025},
  volume = {8},
  number = {8},
  pages = {e2527403},
  doi = {10.1001/jamanetworkopen.2025.27403}
}
Kostenlos starten →